Skip to main content

Advertisement

Table 1 Summary of baseline characteristics and demographics

From: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

  Cross-sectional phase Longitudinal phase
Empty Spiromax followed by empty Turbuhaler (N = 243a) Empty Turbuhaler followed by empty Spiromax (N = 242a) P-value BF Spiromax (N = 197a) BF Turbuhaler (N = 197a) P-value
Age, years, mean (SD) 54.4 (13.8) 53.1 (14.2) 0.309b 53.3 (14.3) 53.1 (14.1) 0.758b
Height, cm, mean (SD) 167.5 (9.1) 169.3 (9.4) 0.022b 168.1 (8.9) 168.8 (9.5) 0.348b
Sex, male, n (%) 91 (37.4) 108 (44.6) 0.108c 81 (41.1) 82 (41.6) 0.919c
FEV1, mean (SD) 2.5 (0.8) 2.6 (0.8) 0.238b 2.5 (0.8) 2.6 (0.9) 0.305b
ACQ-7, mean (SD) 1.4 (0.9) 1.6 (0.9) 0.043b 1.6 (1.0) 1.6 (0.9) 0.257b
Eosinophil levels, mean cells/nL (SD) 0.3 (0.3) 0.3 (0.3) 0.279b 0.3 (0.2) 0.3 (0.2) 0.595b
Medications, n (%)
 Prior medication 199 (81.9) 195 (80.6) 0.711c 179 (90.9) 184 (93.4) 0.350c
 Concomitant medication 240 (98.8) 240 (99.2) 0.656c 194 (98.5) 196 (99.5) 0.315c
  1. ACQ-7 7-item asthma control questionnaire, BF budesonide formoterol, FEV1 forced expiratory volume in 1 second, SD standard deviation
  2. aIntent-to-treat population
  3. bMann-Whitney U Test
  4. cChi-Squared Test